Qinglai Meng   Ph.D
	Professor   Master Supervisor
	Email: qmeng@sxu.edu.cn

Education

1996-2000, B.S. in Biotechnology, Northeast Agriculture University, China

2001-2008, Ph.D. in Microbiology, Wuhan Institute of Virology, Chinese Academy Science, China

Working Experience

2008-2009, Research Associate, National Center for AIDS Control and Prevention, Chinese Center for Disease Control and Prevention, China

2009-2017, Research Associate, Division of Infectious Disease/Department of Dermatology, Case Western Reserve University, U.S.

Research Interests:

Human immunodeficiency virus (HIV) and mycobacterium tuberculosis (Mtb) are two infectious diseases that severely threaten human health, and coinfection of HIV accelerates TB progression and mortality. Our group are examining the role of immune co-inhibitory molecules in immunopathogenesis of HIV infection and HIV/TB coinfection and development of novel strategies to improve the efficacy of diagnosis and treatment of HIV/TB co-infection. The other research interest is development of the high sensitive biosensor based technique for rapid diagnose of antibiotic or anti-retroviral drug resistance of bacteria or HIV

Current projects:

1. Study the role of immune coinhibitory molecules in the impaired TB specific T cell immune responses during HIV/TB co-infection, and evaluate the potential of immune co-inhibitory molecules specific antibodies in improving efficacy of TB diagnosis

2. Study the effect of aberrant expression of immune modulatory molecules on monocytes on persistent inflammation in HIV patients undergoing anti-retroviral treatment

3. Evaluate the potential of stem cell treatment of the persistent inflammation in HIV patients undergoing anti-retroviral treatment

4. Develop novel strategies to rapidly diagnose antibiotic resistance of bacteria and anti-retroviral drug resistance of HIV

5. Examine the efficacy of Alefacept in elimination of HIV reservoir by a non-human primate model

Selected publication:

1. Qinglai Meng, Ismail Sayin, David H. Canaday, Harriet Mayanja-Kizza, Joy Baseke, Zahra Toossi. Immune Activation at Sites of HIV/TB Co-infection contributes to the pathogenesis of HIV-1 disease. Plos One. 2016 Nov 21;11(11):e0166954 (第一作者. IF. 3.057)

2. Qinglai Meng*, David H. Canaday, David J. McDonald, Harriet Mayanja-Kizza, Joy Baseke, Zahra Toossi*. Productive HIV-1 infection is enriched in CD4-CD8- double negative (DN) T cells at pleural sites of dual HIV/TB infection. Archives of Virology. 2016 Jan; 161 (1):181-187 (第一作者及通讯作者. IF. 2.26)

3. Zahra Toossi, Qinglai Meng, Shigou Liu, Harriet Mayanja-Kizza and Christina S. Hirsch. Promotion of expression of APOBEC3G by interferon gamma at sites of HIV/TB dual infection. AIDS Research and Human Retroviruses. 2015 Jul;31(7):692-5（第二作者. IF. 2.325）

4. Qinglai Meng, M R Sandhya Rani, Julia M Sugalski, Chelsey J. Judge, Sarah Phat, Ronald E Blanton, Benigno Rodriguez and Donald D. Anthony. 2014. Natural Cytotoxicity Receptor-Dependent Natural Killer Cytolytic Activity Directed at Hepatitis C Virus (HCV) Is Associated With Liver Inflammation, African American Race, IL28B Genotype, and Response to Pegylated Interferon/Ribavirin Therapy in Chronic HCV Infection. J Infect Dis. 290 (10): 1591-1601（第一作者. IF. 5.997）

5.  Sara J Conry*, Qinglai Meng*, Gareth Hardy, Nicole L Yonkers, Julia M Sugalski, Amy Hirsch, Perica Davitkov, Anita Compan, Yngve Falck-Ytter, Ronald E. Blanton, Benigno Rodriguez, Clifford V Harding and Donald D. Anthony. 2012. Genetically associated CD16⁺56^- NK-cell IFN-?R expression regulates signaling and is implicated in IFN-?-induced HCV decline. J Infect Dis. 205(7):1131-41 (并列第一作者. IF. 5.848)

6.  Qinglai Meng*, Yuezhi Lin*, Jian Ma, Yan Ma, Liping Zhao, Shenwei Li, Kai Yang, Jianhua Zhou, Rongxian Shen, Xiaoyan Zhang and Yiming Shao. 2012. A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine. Viral Immunol. 25(6):477-84 (第一作者. IF. 1.75)

7.  Meng Q*, Lin Y*, Ma J, Ma Y, Zhao L, Li S, Liang H, Zhou J, Shen R, Zhang X and Shao Y. 2011. A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies. Arch Virol. 156(8):1455-62 (第一作者. IF. 2.11)

8.  Meng Q, Li S, Liu L, Xu J, Liu Y, Zhang Y, Zhang X and Shao Y. 2008. Truncation of cytoplasmic tail of EIAV Env increases the pathogenic necrosis. Virus Research. 133(2):201-210. （第一作者. IF. 2.43）

9.  Meng Q, Mecklenburg M, Danielsson B and Xie B. Development of a tRNA-Synthetase Microarray for Protein Analysis. Sensors and materials, Vol 16. No.8 (2004) 401-412 (第一作者. IF. 0.53)

Patent:

Bin Xie, Qinglai Meng, Weihong Xie. “Method of a tRNA-Synthetase Microarray Preparation”. China patent CN1485434.